Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
复制标题
DOI：
10.1038/leu.2008.402
复制
发表时间：
2009-06-01
期刊：
影响因子：
11.4
通讯作者：
Dimopoulos, M. A.
中科院分区：
文献类型：
--
作者：
Kastritis, E.;Zervas, K.;Dimopoulos, M. A.
当新型药物沙利度胺、硼替佐米和来那度胺在临床试验中应用于骨髓瘤患者时，它们与反应、无进展生存期和一些研究中的总生存期（OS）的显著改善相关；然而，它们对未选择的骨髓瘤患者预后的影响尚未得到充分评估。我们比较了1376例未选择的症状性骨髓瘤患者的结果，这些患者在引入沙利度胺之前或之后开始治疗。引入新药物后开始治疗的患者的中位OS延长了12个月(48个月vs 36个月，P
When the novel agents thalidomide, bortezomib and lenalidomide are administered to patients with myeloma in the context of clinical trials, they are associated with a significant improvement in response, progression-free survival and in some studies, overall survival (OS); however, their effect on the outcome of unselected myeloma patients has not been fully assessed. We compared the outcome of 1376 unselected patients with symptomatic myeloma, who started treatment before or after the introduction of thalidomide. The median OS in patients who started treatment after the introduction of novel agents increased by 12 months (48 vs 36 months, P